NEW YORK (GenomeWeb) – Canadian molecular diagnostics company Proteocyte Diagnostics today said that it closed a funding round that raised C$605,000 (US$554,000).

Investors included the Ontario Centres of Excellence, which provided C$250,000 in the financing, as well as a private syndicate of investors. The proceeds will be used to drive commercialization of Proteocyte's Straticyte diagnostic test for oral cancers, the Toronto-based company said. Proteocyte, which was founded in 2011, said on its website that it anticipates launching the test in 18 to 24 months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.